A299660 Stock Overview
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cellid, Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,800.00 |
| 52 Week High | ₩9,370.00 |
| 52 Week Low | ₩3,100.00 |
| Beta | 1.55 |
| 1 Month Change | -14.03% |
| 3 Month Change | -10.80% |
| 1 Year Change | -56.07% |
| 3 Year Change | -94.40% |
| 5 Year Change | -91.57% |
| Change since IPO | -92.56% |
Recent News & Updates
Shareholder Returns
| A299660 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.9% | 2.9% | 2.7% |
| 1Y | -56.1% | 10.0% | 5.8% |
Return vs Industry: A299660 underperformed the KR Biotechs industry which returned 10% over the past year.
Return vs Market: A299660 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A299660 volatility | |
|---|---|
| A299660 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A299660 has not had significant price volatility in the past 3 months.
Volatility Over Time: A299660's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Yuil Kang Chang | www.cellid.co.kr |
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo, a customized immunotherapeutic vaccine; and COVID-19 prevention vaccines.
Cellid, Co., Ltd. Fundamentals Summary
| A299660 fundamental statistics | |
|---|---|
| Market cap | ₩51.69b |
| Earnings (TTM) | -₩11.61b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs A299660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A299660 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩4.86m |
| Gross Profit | -₩4.86m |
| Other Expenses | ₩11.61b |
| Earnings | -₩11.61b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -853.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 29.6% |
How did A299660 perform over the long term?
See historical performance and comparison